

# How to comply with ICH Q11

15 November 2011, Munich, Germany

## Objectives

This pre-conference session **highlights the key principles of the new ICH Q11 Guideline**. You will get to know the essential aspects and approaches of process development and drug substance understanding described in the new Guidance such as

- How to link material attributes and process parameters to drug substances CQAs
- How to apply the concept of Design Space
- How to develop a control strategy
- How to submit relevant information from manufacturing process development in the CTD format

**This pre-conference session ideally complements the following 14th APIC/CEPIC European Conference on Active Pharmaceutical Ingredients.**

## Target Audience

This pre-conference session is designed for all scientists, and persons involved in R&D departments of API manufacturers. Furthermore, the session will be of interest to personnel from production, quality assurance, quality control and regulatory affairs.

## Programme

### The new ICH Q11 Guidance on Development and Manufacture of Drug Substances – an overview

- Goals and scope of the new Guidance
- Fundamentals and key principles of API process development
- The concept of design space
- Control strategy
- Process validation and evaluation
- Submission requirements in the CTD
- ICH Q8, Q9, Q10 – how do they work together with ICH Q11?

### Manufacturing Process Development – General Principles and Process Development Tools

- Drug substance quality link to drug product
- Process development tools
- Critical quality attributes (CQAs)
- Linking material attributes and process parameters to drug substance CQAs
- Design space(s) and real-time release testing

### Knowledge Management and Quality Risk Management during the Lifecycle of a Product

- Quality risk management and informal risk management processes
  - Risk management
  - Risk assessment
  - Risk control
- Knowledge management/prior knowledge and development studies
- Systematic approach to manage knowledge throughout the lifecycle

### Process Validation and Design Space in early development

- Points to consider regarding
  - number and complexity of the process being validated
  - level of process variability
  - process knowledge available
- Product related and process related impurities
- Process variability, variability of material attributes and the design space

### How to submit process development information via the CTD

- Where and how to submit development related information in the CTD - specific suggestions for
  - quality risk management and process development
  - CQAs
  - Design Space
  - Control strategy
- Where to include summaries and detailed information

### APIC Comments to the ICH Q11 Draft Guideline

## Speakers



### Karl Metzger, gmPlan GmbH, Germany

Karl Metzger is Managing Partner of gmPlan GmbH. He was formerly Management responsible for the Welding's integrated Management System and deputy QP for APIs.



### Filipe Neves, Hovione, Portugal

Filipe Neves is Assistant Engineer in the R&D Particle Design Discipline at Hovione FarmaCiencia SA, Loures, Portugal.



### Ron Ogilvie, Pfizer, UK

Ron Ogilvie is a CMC adviser in Pfizer's Global Regulatory CMC group, chair Pfizer's Impurity Council and has been involved in Q11 development as part of EFPIA EWG support team.



### Luisa Paulo, Hovione, Portugal

Compliance Director at Hovione and Vice Chair of APIC's Good Manufacturing Practices & Quality Assurance Working Group.



### Tom Sam, Merck Sharp & Dohme, UK

Tom Sam is Head Global CMC Regulatory Affairs Merck Sharp & Dohme, Oss, The Netherlands



### Elmar Wenzel, Freelance Consultant, Germany

Mr Wenzel was formerly head of API production at the Plankstadt site of AstraZeneca, now Corden Pharma. He is now freelance consultant.

